Prehabilitation as a Strategy to Modulate the Tumor Microenvironment in Pancreatic Cancer
5 affiliations
- 1Texas A&M School of Engineering Medicine, Texas A&M University, Houston, TX 77030, USA
- 2Department of Surgery, Houston Methodist Hospital, Houston, TX 77030, USA
- 3Houston Methodist Neal Cancer Center, Houston, TX 77030, USA
- 4Immunomonitoring Core, Houston Methodist Neal Cancer Center, Houston, TX 77030, USA
- 5Department of Surgery, J.C. Walter Jr. Transplant Center, Center for Critical Care, Houston Methodist Hospital, Houston, TX 77030, USA
Abstract
Multimodal prehabilitation aims to enhance resilience to cancer therapy through exercise, nutrition, and psychological optimization. While prehabilitation can improve physical condition and functional status, its biologic influence on the tumor microenvironment (TME) remains poorly characterized. In pancreatic ductal adenocarcinoma (PDAC), the TME is dominated by immunosuppressive and desmoplastic features that limit immune cell infiltration and therapeutic efficacy. As an exploratory pilot analysis, this study characterized the cellular composition, spatial relationships, and functional signaling of the pancreatic TME in patients who underwent prehabilitation prior to surgical resection and those who did not. Tumor samples from eight patients (four prehabilitation, four control) were analyzed with a 34-plex protein panel using Imaging Mass Cytometry (IMC), categorizing the tumor–immune landscape and functional status at the single-cell resolution. Prehabilitation tumors demonstrated reduced neutrophil and epithelial/tumor cell density and enrichment of Natural Killer (NK), CD4+, and CD8+ T cells. Spatial analysis revealed an immune-permissive architecture in prehabilitation tumors, in contrast to immune-resistant patterns in controls. Functional marker analysis showed reduced activation and pro-tumor signaling in immunosuppressive populations, including Tregs (HLADR, pAkt, pNFκB) and Collagen+ CAFs (NOS2, pERK, pNFκB, pSTAT3). These preliminary findings raise the possibility that prehabilitation is associated with an immune-permissive TME in PDAC, supporting further investigation of its immunomodulatory potential in larger, prospectively designed cohorts.
Related
- Strategy for early diagnosis of pancreatic cancer
- Integrated pharmacology and validation reveal Formononetin upregulates GSTM2 to modulate prostate cancer immune microenvironment via ROS/STAT3-driven chemokine reprogramming
- Current Role of Endoscopic Ultrasonography in the Early Detection of Pancreatic Cancer: Recognition of Indirect Imaging Findings and Diagnostic Strategy
- Naringenin in pancreatic cancer: emerging evidence on the tumor immune-stromal microenvironment, immunometabolic reprogramming, microbiota-host crosstalk, and therapeutic resistance
- Conserved Metastatic Cell States and Spatial Immune Microenvironment Remodeling Define Pancreatic Cancer Liver Metastases
BibTeX
@article{sandeep2026prehabilitation,
title = {{Prehabilitation as a Strategy to Modulate the Tumor Microenvironment in Pancreatic Cancer}},
author = {Sanjna Sandeep and Jason Schutt and Kelvin Allenson and Renee Stubbins and Junjun Zheng and Shu-Hsia Chen and Atiya Dhala},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27198900},
url = {https://www.mdpi.com/1422-0067/27/19/8900},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Prehabilitation as a Strategy to Modulate the Tumor Microenvironment in Pancreatic Cancer
AU - Sanjna Sandeep
AU - Jason Schutt
AU - Kelvin Allenson
AU - Renee Stubbins
AU - Junjun Zheng
AU - Shu-Hsia Chen
AU - Atiya Dhala
PY - 2026
DA - 2026/10/07
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27198900
UR - https://www.mdpi.com/1422-0067/27/19/8900
AB - Multimodal prehabilitation aims to enhance resilience to cancer therapy through exercise, nutrition, and psychological optimization. While prehabilitation can improve physical condition and functional status, its biologic influence on the tumor microenvironment (TME) remains poorly characterized. In pancreatic ductal adenocarcinoma (PDAC), the TME is dominated by immunosuppressive and desmoplastic features that limit immune cell infiltration and therapeutic efficacy. As an exploratory pilot analysis, this study characterized the cellular composition, spatial relationships, and functional signaling of the pancreatic TME in patients who underwent prehabilitation prior to surgical resection and those who did not. Tumor samples from eight patients (four prehabilitation, four control) were analyzed with a 34-plex protein panel using Imaging Mass Cytometry (IMC), categorizing the tumor–immune landscape and functional status at the single-cell resolution. Prehabilitation tumors demonstrated reduced neutrophil and epithelial/tumor cell density and enrichment of Natural Killer (NK), CD4+, and CD8+ T cells. Spatial analysis revealed an immune-permissive architecture in prehabilitation tumors, in contrast to immune-resistant patterns in controls. Functional marker analysis showed reduced activation and pro-tumor signaling in immunosuppressive populations, including Tregs (HLADR, pAkt, pNFκB) and Collagen+ CAFs (NOS2, pERK, pNFκB, pSTAT3). These preliminary findings raise the possibility that prehabilitation is associated with an immune-permissive TME in PDAC, supporting further investigation of its immunomodulatory potential in larger, prospectively designed cohorts.
SN - 1422-0067
ER -